Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Soluble serum VCAM-1, whole blood mRNA expression and treatment response in natalizumab-treated multiple sclerosis

Research output: Contribution to journalJournal articleResearchpeer-review

  1. The role of gluten in multiple sclerosis: A systematic review

    Research output: Contribution to journalReviewResearchpeer-review

  2. Clinical utility of anti-MOG antibody testing in a Danish cohort

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Increased cerebrospinal fluid chitinase 3-like 1 and neurofilament light chain in pediatric acquired demyelinating syndromes

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Patient awareness about family planning represents a major knowledge gap in multiple sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Small-scale geographical variation in multiple sclerosis: A case-control study using Danish register data 1971-2013

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Functional neuroimaging of recovery from motor conversion disorder: A case report

    Research output: Contribution to journalReviewResearchpeer-review

  2. Structural and cognitive correlates of fatigue in progressive multiple sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Comparative effectiveness of teriflunomide and dimethyl fumarate: A nationwide cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Treatment escalation leads to fewer relapses compared with switching to another moderately effective therapy

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. The neutrophil-to-lymphocyte ratio is associated with multiple sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: Natalizumab reduces disease activity in multiple sclerosis (MS). Natalizumab binds to the very late antigen-4 and inhibits vascular cell adhesion molecule-1 (VCAM-1)-mediated transmigration of immune cells across the blood-brain-barrier. This is associated with decreased serum concentrations of soluble (s)VCAM-1 and an altered composition of immune cell-subsets in the blood.

OBJECTIVE: We aimed to examine if sVCAM-1 serum concentrations and whole blood mRNA expression levels of immune activation biomarkers is associated with disease activity in natalizumab-treated MS-patients.

METHODS: sVCAM-1 serum concentrations and whole blood mRNA expression were measured in blood samples from untreated RRMS-patients and from two independent groups of natalizumab-treated patients.

RESULTS: sVCAM-1 serum concentrations and whole blood expression of HLX1 and IL1B mRNA were lower, whereas expression of EBI3 mRNA was higher in natalizumab-treated MS-patients. Five genes were differentially expressed in clinically unstable natalizumab-treated MS-patients in the discovery but not in the validation group.

CONCLUSION: Decreased serum concentrations of sVCAM-1 and altered whole blood mRNA expression levels of a panel of immunomarkers, associated with natalizumab-treatment, are not sensitive markers of MS disease activity. However, decreased expression of pro-inflammatory HLX1 and IL1B and increased expression of immunoregulatory EBI3 may indicate a less pathogenic immune activation status in natalizumab-treated MS.

Original languageEnglish
JournalMultiple Sclerosis and Related Disorders
Volume10
Pages (from-to)66-72
Number of pages7
ISSN2211-0348
DOIs
Publication statusPublished - Nov 2016

ID: 49732471